# 04_QA_REPORT.md

# QA Report

---

# Identity

| Field | Value |
|---|---|
| PP ID | PP-0185 |
| Title | Tumor Mutational Burden (TMB) |
| QA Report ID | QA-PP-0185 |
| Version | 1.0.0 |
| QA Mode | Gold Population Package QA |
| Date | 2026-08-09 |
| Final Status | PASS — GOLD — READY FOR INTEGRATION |

---

# QA Objective

This QA report evaluates the complete PP-0185 Gold Population Package against:

1. the approved and locked PP-0185 Decision Batch;
2. the locked FREEZE GOLD POPULATION PACKAGE SPECIFICATION v1.0;
3. CORE_WORKING_RULES v1.6;
4. the approved Discussion Batch depth/format reference;
5. the relevant project Source Materials;
6. adjacent Population Package boundaries;
7. source-grounded clinical accuracy;
8. patient-facing educational quality;
9. repository readiness.

The package contains:

- `01_CKO.md`
- `02_KNOWLEDGE_PASSPORT.md`
- `03_PRIMARY_EVIDENCE_PACKAGE.md`
- `04_QA_REPORT.md`

---

# Layer 1 — Content QA

## 1.1 Scope Respect

**PASS**

The package answers the single atomic educational question:

> What is TMB, what does TMB-H mean, and why can it matter in gastric cancer?

It does not expand into a general NGS manual, full molecular-report interpretation package, or immunotherapy treatment package.

---

## 1.2 Completeness

**PASS**

The package includes the required conceptual content:

- TMB definition;
- mutations per megabase;
- TMB-H;
- ≥10 mutations/Mb threshold;
- genomic testing relationship;
- NGS relationship;
- clinical relevance;
- immunotherapy relevance;
- biomarker distinctions;
- limitations;
- evidence gaps;
- patient-facing explanation;
- common misconceptions;
- Knowledge Graph.

---

## 1.3 Atomicity

**PASS**

The package remains focused on one educational question.

It does not become an encyclopedic package covering every aspect of precision oncology.

---

## 1.4 Clinical Knowledge Block Completeness

**PASS**

The CKO provides independent knowledge blocks covering:

1. What TMB is.
2. What mutational burden means.
3. Mutations per megabase.
4. TMB-H.
5. TMB as a genomic biomarker.
6. TMB/NGS relationship.
7. Immune relevance.
8. Advanced gastric-cancer relevance.
9. Pembrolizumab context.
10. KEYNOTE-158 evidence limitation.
11. MSI/MMR distinction.
12. PD-L1 distinction.
13. HER2/CLDN18.2 distinction.
14. Molecular classification distinction.
15. Assay dependence.
16. What TMB cannot tell.
17. Interpretation of high/low results.
18. Longitudinal limitations.
19. Patient explanation.
20. Misconceptions.

---

## 1.5 Boundary Completeness

**PASS**

The package clearly separates:

- Core;
- Supporting;
- Explicitly Excluded;
- Delegated-to PP.

The boundary is ownership-oriented and non-duplicative.

---

# Layer 2 — Clinical QA

## 2.1 Source-Grounded Clinical Claims

**PASS**

Core claims are grounded in the supplied NCCN Gastric Cancer Version 2.2026 material.

NCCN explicitly identifies TMB-H status among biomarkers implicated in advanced gastric-cancer management and identifies NGS as a method capable of assessing TMB.

---

## 2.2 TMB-H Threshold

**PASS**

The package uses:

**≥10 mutations/megabase**

as the current NCCN gastric-cancer treatment-pathway threshold for TMB-H.

The wording preserves clinical context and does not incorrectly present this as a universal assay-independent biological cutoff.

---

## 2.3 Treatment Context

**PASS**

Pembrolizumab is described only as a treatment-context anchor.

The package does not convert TMB-H into an individualized prescription.

---

## 2.4 KEYNOTE-158 Evidence

**PASS**

The package accurately preserves the NCCN-described findings:

- 102 TMB-H patients;
- ORR 29%;
- CR 4%;
- median duration of response not reached;
- 50% of responders with duration ≥24 months.

---

## 2.5 Gastric-Specific Evidence Limitation

**PASS — CRITICAL CHECK**

The package explicitly states the NCCN limitation:

**No gastroesophageal cancer patients were included in the KEYNOTE-158 TMB analysis.**

This prevents the common error of presenting the evidence as a gastric-specific efficacy dataset.

---

## 2.6 Biomarker Distinctions

**PASS**

The package does not equate:

- TMB with MSI-H;
- TMB with dMMR;
- TMB with PD-L1;
- TMB with HER2;
- TMB with CLDN18.2;
- TMB-H with molecular classification.

---

## 2.7 Unsupported Certainty

**PASS**

The package avoids:

- “TMB-H guarantees response”;
- “TMB-H mandates immunotherapy”;
- “low TMB excludes immunotherapy”;
- “TMB determines treatment”;
- “TMB-H is a molecular subtype.”

---

## 2.8 Safety

**PASS**

No individualized medical advice is provided.

The package consistently directs clinical decisions toward the full clinical and biomarker context.

---

# Layer 3 — Educational QA

## 3.1 Patient-Facing Language

**PASS**

Technical terms are introduced and explained.

Examples:

- TMB;
- TMB-H;
- megabase;
- NGS;
- genomic biomarker.

---

## 3.2 Logical Flow

**PASS**

The educational progression is:

**Definition**
→ **Measurement**
→ **TMB-H**
→ **Genomic testing**
→ **Biological rationale**
→ **Clinical relevance**
→ **Evidence**
→ **Limitations**
→ **Interpretation**
→ **Common misconceptions**

---

## 3.3 Conceptual Clarity

**PASS**

The package repeatedly distinguishes:

> biomarker meaning

from:

> treatment decision.

This is essential for patient-facing precision-oncology education.

---

## 3.4 Misconception Control

**PASS**

The CKO addresses high-risk misconceptions including:

- TMB-H as a single mutation;
- TMB-H = MSI-H;
- TMB as an IHC test;
- TMB-H guaranteeing immunotherapy response;
- TMB-H automatically mandating treatment;
- ≥10 mutations/Mb as a universal cutoff;
- TMB-H as a molecular subtype;
- low TMB excluding immunotherapy;
- TMB alone determining treatment;
- gastric-specific overinterpretation of KEYNOTE-158.

---

## 3.5 Reading Level

**PASS**

The package follows:

- short paragraphs;
- one concept per paragraph;
- plain-language explanations;
- limited jargon;
- neutral tone;
- no sensational language.

---

# Layer 4 — Governance QA

## 4.1 Governance Compliance

**PASS**

The package follows the locked Gold Population Package architecture:

```text
01_CKO.md
02_KNOWLEDGE_PASSPORT.md
03_PRIMARY_EVIDENCE_PACKAGE.md
04_QA_REPORT.md
```

---

## 4.2 Discussion Depth Compliance

**PASS — ABSOLUTE DEPTH RULE**

The package was produced using the stored approved Discussion Batch and Gold artifact references as the minimum depth baseline.

The package was **not compacted**.

No artifact was intentionally shortened to a summary-level output.

The clinical content is expanded sufficiently to preserve:

- conceptual explanation;
- clinical reasoning;
- evidence discussion;
- boundary ownership;
- misconceptions;
- limitations;
- Knowledge Graph implications;
- evidence traceability;
- QA verification.

The depth is therefore **equal to or deeper than the established Gold reference standard**, not shallower.

---

## 4.3 Artifact Structure Compliance

**PASS**

All four required artifacts are present.

The locked specification requires four governed artifacts and does not permit redesign of the architecture.

---

## 4.4 Evidence Traceability

**PASS**

Important clinical claims are mapped to:

- NCCN Gastric Cancer Version 2.2026;
- NCCN Gastric Cancer Discussion Version 2.2026;
- supporting educational sources where used.

---

## 4.5 Source-First Rule

**PASS**

Relevant project Source Files were searched before production.

The package uses the project clinical materials as the primary evidence basis.

No unsupported external clinical claim was silently inserted.

---

## 4.6 Adjacent-Package Overlap

**PASS**

The package explicitly resolves ownership with:

- PP-0180;
- PP-0181;
- PP-0182;
- PP-0183;
- PP-0184;
- PP-0186;
- PP-0187;
- PP-0188;
- PP-0189;
- PP-0190;
- PP-0191.

No substantive ownership is duplicated.

---

## 4.7 Knowledge Graph

**PASS**

The package identifies:

- prerequisites;
- related packages;
- recommended next package;
- downstream/delegated molecular and treatment concepts.

---

## 4.8 Versioning

**PASS**

Version:

**1.0.0**

Semantic versioning is used.

---

## 4.9 Repository Readiness

**PASS**

The four artifacts use the required filenames and are packaged under the PP-specific directory.

---

# Cross-Artifact Consistency Check

| Check | Result |
|---|---|
| PP ID consistent across all artifacts | PASS |
| Title consistent across all artifacts | PASS |
| Version consistent | PASS |
| Scope consistent | PASS |
| Exclusions consistent | PASS |
| Boundary consistent | PASS |
| Evidence hierarchy consistent | PASS |
| Knowledge Graph consistent | PASS |
| Clinical claims consistent | PASS |
| QA status consistent | PASS |
| Final status consistent | PASS |

---

# Critical Clinical Claim Verification

| Claim | Verification |
|---|---|
| TMB is a genomic biomarker | PASS |
| TMB-H is a high mutational burden category | PASS |
| ≥10 mutations/Mb is the current NCCN gastric-cancer treatment-context threshold | PASS |
| NGS can assess TMB | PASS |
| TMB-H has selected treatment relevance | PASS |
| Pembrolizumab is listed in selected TMB-H circumstances | PASS |
| TMB-H does not independently prescribe treatment | PASS |
| TMB is distinct from MSI/MMR | PASS |
| TMB is distinct from PD-L1 | PASS |
| TMB is distinct from HER2/CLDN18.2 | PASS |
| KEYNOTE-158 TMB analysis had 102 TMB-H patients | PASS |
| KEYNOTE-158 TMB analysis ORR was 29% | PASS |
| CR rate was 4% | PASS |
| Median duration of response was not reached | PASS |
| 50% of responders had duration ≥24 months | PASS |
| No gastroesophageal cancer patients were included in the TMB analysis | PASS |

---

# Final QA Decision

## **PASS**

All four QA layers pass.

No critical clinical, educational, governance, evidence-traceability, or architecture defect was identified.

The package is suitable for Gold integration.

---

# Final Status

**PASS — GOLD — READY FOR INTEGRATION.**
